KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Other Working Capital Changes (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Other Working Capital Changes data on record, last reported at $2.7 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 94.47% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $34.5 million, up 61.21%, while the annual FY2025 figure was $34.5 million, 61.21% up from the prior year.
  • Other Working Capital Changes reached $2.7 million in Q4 2025 per EW's latest filing, down from $7.9 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $49.6 million in Q2 2023 and bottomed at -$33.2 million in Q3 2021.
  • Average Other Working Capital Changes over 5 years is $6.9 million, with a median of $5.7 million recorded in 2022.
  • Peak YoY movement for Other Working Capital Changes: soared 1625.0% in 2024, then plummeted 622.22% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $20.0 million in 2021, then tumbled by 38.5% to $12.3 million in 2022, then plummeted by 126.02% to -$3.2 million in 2023, then skyrocketed by 1625.0% to $48.8 million in 2024, then plummeted by 94.47% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $2.7 million in Q4 2025, $7.9 million in Q3 2025, and -$4.7 million in Q2 2025.